Vertex Pharmaceuticals Inc (VRTX)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	7,360,000	7,333,300	7,227,600	7,021,300	6,787,500	6,600,020	6,349,830	6,000,580	5,703,200	5,410,270	5,029,740	4,808,780	4,640,780	4,462,920	3,942,417	3,442,341	2,887,551	2,434,424	2,329,263	2,195,353
Revenue (ttm)	US$ in thousands	9,803,200	9,596,700	9,444,700	9,144,300	8,863,500	8,628,770	8,277,080	7,873,370	7,499,400	7,066,960	6,622,470	6,355,190	6,147,530	5,935,020	5,347,582	4,763,428	4,106,025	3,577,111	3,416,521	3,232,116
Gross profit margin		75.08%	76.41%	76.53%	76.78%	76.58%	76.49%	76.72%	76.21%	76.05%	76.56%	75.95%	75.67%	75.49%	75.20%	73.72%	72.27%	70.32%	68.06%	68.18%	67.92%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $7,360,000K ÷ $9,803,200K
= 75.08%

The gross profit margin of Vertex Pharmaceuticals, Inc. has been relatively stable over the past eight quarters, ranging from 87.21% to 88.13%. Generally, the company has maintained a high gross profit margin, indicating efficient cost management and strong pricing power in its operations. Despite minor fluctuations, the overall trend suggests consistent profitability in the company's core business activities. Further investigation into the underlying factors contributing to the fluctuations may provide additional insights into the company's performance and future growth prospects.